AKT1 and prostate carcinoma: Recent work has shown that eATP stimulates the activation of PI3K/Akt through purinergic receptors, promoting anoikis resistance and metastasis in osteosarcoma, hepatocellular carcinoma, and prostate cancer (Fig. 3a).